Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies
Abstract Introduction Psoriasis is a chronic immune-mediated disease with significant systemic implications. Tildrakizumab, an IL-23p19 inhibitor, has demonstrated efficacy in moderate-to-severe plaque psoriasis. Higher doses may be beneficial for patients with elevated body weight or greater diseas...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-05-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01442-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850243532959252480 |
|---|---|
| author | Emanuele Trovato Tommaso Bianchelli Giulia Odorici Aldo Cuccia Vito Giuseppe Di Lernia Claudia Lasagni Marco Manfredini Massimiliano Nicolini Giulia Rech Francesca Satolli Alessandra Cartocci Federico Bardazzi Anna Campanati |
| author_facet | Emanuele Trovato Tommaso Bianchelli Giulia Odorici Aldo Cuccia Vito Giuseppe Di Lernia Claudia Lasagni Marco Manfredini Massimiliano Nicolini Giulia Rech Francesca Satolli Alessandra Cartocci Federico Bardazzi Anna Campanati |
| author_sort | Emanuele Trovato |
| collection | DOAJ |
| description | Abstract Introduction Psoriasis is a chronic immune-mediated disease with significant systemic implications. Tildrakizumab, an IL-23p19 inhibitor, has demonstrated efficacy in moderate-to-severe plaque psoriasis. Higher doses may be beneficial for patients with elevated body weight or greater disease burden. This study evaluates the effectiveness of tildrakizumab 200 mg in a real-world setting, analyzing outcomes based on weight, Psoriasis Area Severity Index (PASI), body mass index (BMI), and prior biologic exposure. Methods A multicenter retrospective study was conducted across 10 Italian hospitals. Adult patients (≥ 18 years) with moderate-to-severe plaque psoriasis treated with tildrakizumab 200 mg for ≥ 36 weeks were included. Patients were stratified by weight (≥ 90 kg vs. < 90 kg), BMI (≥ 30 vs. < 30), PASI (≥ 15 vs. < 15), and biologic history (naïve vs. biologic (bio)-experienced). PASI100 response rates at 36 weeks were assessed. Statistical analyses included Fisher’s exact test (p < 0.05 significant). Results Among 137 patients, PASI100 response rates were 67.1% for patients < 90 kg vs. 49.2% for ≥ 90 kg (p = 0.04), 61.5% for PASI < 15 vs. 50% for PASI ≥ 15 (p = 0.03), and 60.8% for bio-naïve vs. 57.1% for bio-experienced (p = 0.08). BMI ≥ 30 was associated with lower PASI100 (44.2%) compared to BMI < 30 (61.4%) (p = 0.05). Despite subgroup differences, all patients exhibited clinical improvement. Conclusion Tildrakizumab 200 mg effectively treated moderate-to-severe psoriasis across diverse patient subgroups. While higher weight and PASI were associated with slightly lower PASI100 rates, significant improvements were observed, supporting its role in difficult-to-treat patients. |
| format | Article |
| id | doaj-art-a89e275636a1459680f2f089a4e16806 |
| institution | OA Journals |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-a89e275636a1459680f2f089a4e168062025-08-20T01:59:57ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-05-011571941195210.1007/s13555-025-01442-xEffectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous TherapiesEmanuele Trovato0Tommaso Bianchelli1Giulia Odorici2Aldo Cuccia3Vito Giuseppe Di Lernia4Claudia Lasagni5Marco Manfredini6Massimiliano Nicolini7Giulia Rech8Francesca Satolli9Alessandra Cartocci10Federico Bardazzi11Anna Campanati12Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of SienaDermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, INRCA-IRCCS HospitalSection of Dermatology, Department of Medical Sciences, University of FerraraUnit of Dermatology, San Donato HospitalDermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio EmiliaDermatology Clinic, University of Modena and Reggio EmiliaDermatology Clinic, University of Modena and Reggio EmiliaCarlo Urbani HospitalDivision of Dermatology, “U.O. Multizonale APSS”Dermatolgy Unit, Department of Medicine and Surgery, University of ParmaDermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of SienaDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-MalpighiDepartment of Clinical and Molecular Sciences, Dermatological Clinic, Università Politecnica delle MarcheAbstract Introduction Psoriasis is a chronic immune-mediated disease with significant systemic implications. Tildrakizumab, an IL-23p19 inhibitor, has demonstrated efficacy in moderate-to-severe plaque psoriasis. Higher doses may be beneficial for patients with elevated body weight or greater disease burden. This study evaluates the effectiveness of tildrakizumab 200 mg in a real-world setting, analyzing outcomes based on weight, Psoriasis Area Severity Index (PASI), body mass index (BMI), and prior biologic exposure. Methods A multicenter retrospective study was conducted across 10 Italian hospitals. Adult patients (≥ 18 years) with moderate-to-severe plaque psoriasis treated with tildrakizumab 200 mg for ≥ 36 weeks were included. Patients were stratified by weight (≥ 90 kg vs. < 90 kg), BMI (≥ 30 vs. < 30), PASI (≥ 15 vs. < 15), and biologic history (naïve vs. biologic (bio)-experienced). PASI100 response rates at 36 weeks were assessed. Statistical analyses included Fisher’s exact test (p < 0.05 significant). Results Among 137 patients, PASI100 response rates were 67.1% for patients < 90 kg vs. 49.2% for ≥ 90 kg (p = 0.04), 61.5% for PASI < 15 vs. 50% for PASI ≥ 15 (p = 0.03), and 60.8% for bio-naïve vs. 57.1% for bio-experienced (p = 0.08). BMI ≥ 30 was associated with lower PASI100 (44.2%) compared to BMI < 30 (61.4%) (p = 0.05). Despite subgroup differences, all patients exhibited clinical improvement. Conclusion Tildrakizumab 200 mg effectively treated moderate-to-severe psoriasis across diverse patient subgroups. While higher weight and PASI were associated with slightly lower PASI100 rates, significant improvements were observed, supporting its role in difficult-to-treat patients.https://doi.org/10.1007/s13555-025-01442-xPsoriasisBiologicsTildrakizumabBody mass indexPasiWeight |
| spellingShingle | Emanuele Trovato Tommaso Bianchelli Giulia Odorici Aldo Cuccia Vito Giuseppe Di Lernia Claudia Lasagni Marco Manfredini Massimiliano Nicolini Giulia Rech Francesca Satolli Alessandra Cartocci Federico Bardazzi Anna Campanati Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies Dermatology and Therapy Psoriasis Biologics Tildrakizumab Body mass index Pasi Weight |
| title | Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies |
| title_full | Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies |
| title_fullStr | Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies |
| title_full_unstemmed | Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies |
| title_short | Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies |
| title_sort | effectiveness of tildrakizumab 200 mg in moderate to severe plaque psoriasis a multicenter real world study analyzing patient outcomes by weight pasi bmi and previous therapies |
| topic | Psoriasis Biologics Tildrakizumab Body mass index Pasi Weight |
| url | https://doi.org/10.1007/s13555-025-01442-x |
| work_keys_str_mv | AT emanueletrovato effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT tommasobianchelli effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT giuliaodorici effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT aldocuccia effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT vitogiuseppedilernia effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT claudialasagni effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT marcomanfredini effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT massimilianonicolini effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT giuliarech effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT francescasatolli effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT alessandracartocci effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT federicobardazzi effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies AT annacampanati effectivenessoftildrakizumab200mginmoderatetosevereplaquepsoriasisamulticenterrealworldstudyanalyzingpatientoutcomesbyweightpasibmiandprevioustherapies |